|
|||||
|
|
Non-coding RNAs as therapeutic targets for preventing myocardial ischemia-reperfusion injury |
|
| Authors: | Sang-Bing Ong Khairunnisa Katwadi Xiu-Yi Kwek Nur Izzah Ismail Kroekkiat Chinda Sang-Ging Ong |
| Affiliation: | 1. Signature Research Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore;2. Department of Biomedical Engineering, Faculty of Engineering, University of Malaya, Kuala Lumpur, Malaysia;3. Department of Physiology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand;4. Biomedical Research Unit in Cardiovascular Sciences (BRUCS), Naresuan University, Phitsanulok, Thailand;5. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA |
| Abstract: | Introduction: New treatments are required to improve clinical outcomes in patients with acute myocardial infarction (AMI), for reduction of myocardial infarct (MI) size and preventing heart failure. Following AMI, acute ischemia/reperfusion injury (IRI) ensues, resulting in cardiomyocyte death and impaired cardiac function. Emerging studies have implicated a fundamental role for non-coding RNAs (microRNAs miRNA], and more recently long non-coding RNAs lncRNA]) in the setting of acute myocardial IRI. Areas covered: In this article, we discuss the roles of miRNAs and lncRNAs as potential biomarkers and therapeutic targets for the detection and treatment of AMI, review their roles as mediators and effectors of cardioprotection, particularly in the settings of interventions such as ischemic pre- and post-conditioning (IPC & IPost) as well as remote ischemic conditioning (RIC), and highlight future strategies for targeting ncRNAs to reduce MI size and prevent heart failure following AMI. Expert opinion: Investigating the roles of miRNAs and lncRNAs in the setting of AMI has provided new insights into the pathophysiology underlying acute myocardial IRI, and has identified novel biomarkers and therapeutic targets for detecting and treating AMI. Pharmacological and genetic manipulation of these ncRNAs has the therapeutic potential to improve clinical outcomes in AMI patients. |
| Keywords: | Ischemia-reperfusion injury long non-coding RNA microRNAs non-coding RNAs acute myocardial infarction cardioprotection ischemic conditioning |